Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
Margaret A. Tempero(UCSF Helen Diller Family Comprehensive Cancer Center), Mokenge P. Malafa(Moffitt Cancer Center), E. Gabriela Chiorean(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Brian G. Czito(Cancer Institute (WIA)), Courtney L. Scaife(University of Utah), Amol Narang(Sidney Kimmel Comprehensive Cancer Center), Christos Fountzilas, Brian M. Wolpin(Dana-Farber Brigham Cancer Center), Mahmoud M. Al-Hawary(University of Michigan), Horacio J. Asbun, Stephen W. Behrman(St. Jude Children's Research Hospital), Al B. Benson(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Ellen F. Binder(Barnes-Jewish Hospital), Dana B. Cardin(Breast Cancer Research Foundation), Charles Cha(Smilow Cancer Hospital), Vincent Chung(City Of Hope National Medical Center), Mary Dillhoff(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Efrat Dotan(Fox Chase Cancer Center), Cristina R. Ferrone(Massachusetts General Hospital), George A. Fisher(Cancer Institute (WIA)), Jeffrey M. Hardacre(Cleveland Clinic), William G. Hawkins(Barnes-Jewish Hospital), Andrew H. Ko(UCSF Helen Diller Family Comprehensive Cancer Center), Noelle K. LoConte(University of Wisconsin Carbone Cancer Center), Andrew M. Lowy(University of California San Diego), Cassadie Moravek(Pancreatic Cancer Action Network), Eric K. Nakakura(UCSF Helen Diller Family Comprehensive Cancer Center), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Jorge Obando(Cancer Institute (WIA)), Sushanth Reddy(University of Alabama at Birmingham), Sarah P. Thayer(Susan Thompson Buffett Foundation), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Jennifer L. Burns(National Comprehensive Cancer Network), Griselda Zuccarino-Catania(National Comprehensive Cancer Network)
Cited by 370
Abstract
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.
Related Papers
No related papers found
Powered by citation graph analysis